title: Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
abstract: BACKGROUND
  Fosaprepitant may be associated with infusion site adverse events (AEs), and these adverse events possibly vary according to chemotherapy regimen.
  
  
  METHODS
  267 oncology patients who were administered anthracycline- or cisplatin-based regimens were retrospectively studied. Multivariate logistic regression was performed in stratified analyses to evaluate potential regimen-specific effects of fosaprepitant.
  
  
  RESULTS
  41.7% of patients administered fosaprepitant experienced infusion site AEs. On the other hand, only 10.9% of patients administered aprepitant experienced AEs. Multivariate analysis showed a statistically significant overall increased risk of infusion site reaction associated with fosaprepitant (p<0.001), but when evaluated separately according to chemotherapy regimen, this relationship appeared to be largely confined to patients receiving an anthracycline-based regimen (OR=12.95, 95%CI=5.74-29.20). No association was observed among patients on cisplatin-based regimens. A test for interaction was statistically significant (p=0.001).
  
  
  CONCLUSIONS
  Fosaprepitant is associated with an elevated risk of infusion site reaction in patients receiving anthracyclines.
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan Division of Pulmonary Medicine, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan.
authors.forename: Takeo
authors.initials: T
authors.lastname: Fujii
authors.affiliation: Division of Pulmonary Medicine, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan nina@luke.ac.jp.
authors.forename: Naoki
authors.initials: N
authors.lastname: Nishimura
authors.affiliation: Department of Human Genetics and Disease Diversity, Tokyo Medical and Dental University, Tokyo, Japan Center for Clinical Epidemiology, St. Luke's Life Science Institute, Tokyo, Japan.
authors.forename: Kevin Y
authors.initials: KY
authors.lastname: Urayama
authors.affiliation: Breast Center/Oncology Center, St. Luke's International Hospital, Tokyo, Japan.
authors.forename: Hisako
authors.initials: H
authors.lastname: Kanai
authors.affiliation: Department of Pharmacology, St. Luke's International Hospital, Tokyo, Japan.
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Ishimaru
authors.affiliation: Department of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan.
authors.forename: Junko
authors.initials: J
authors.lastname: Kawano
authors.affiliation: Center for Clinical Epidemiology, St. Luke's Life Science Institute, Tokyo, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Takahashi
authors.affiliation: Department of Breast Surgery, St. Luke's International Hospital, Tokyo, Japan.
authors.forename: Hideko
authors.initials: H
authors.lastname: Yamauchi
authors.affiliation: Division of Medical Oncology, Department of Internal Medicine, St. Luke's International Hospital, Tokyo, Japan.
authors.forename: Teruo
authors.initials: T
authors.lastname: Yamauchi
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines / Q000008:administration & dosage; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D012189:Retrospective Studies; D012871:Skin Diseases / Q000139:chemically induced*
chemical_list: D018943:Anthracyclines; D000932:Antiemetics; D009025:Morpholines; C579707:fosaprepitant; D002945:Cisplatin
keywords: Fosaprepitant; anthracycline; cisplatin; infusion site adverse events